Double-blind randomized controlled trial of the routine perioperative use of terlipressin in adult living donor liver transplantation

What Was Tested

Researchers studied Terlipressin in this randomized controlled trial publication.

Its role and safety profile have never been evaluated in a double-blind randomized controlled trial (RCT).

This was a single-center double-blind RCT.

Who Took Part

According to the abstract, 41 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Consenting adults with chronic liver disease and low risk of posttransplant renal dysfunction undergoing their first LDLT were randomized.

A total of 41 patients were enrolled in the trial (TpG, 21; PbG, 20).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Terlipressin and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Terlipressin.

Some patients received a placebo instead of Terlipressin, giving a reference point.

What Was Measured

Its role and safety profile have never been evaluated in a double-blind randomized controlled trial (RCT).

The primary endpoint was portal pressure after arterial reperfusion.

The subject headings attached to it are Acute Kidney Injury, Ascites, Bradycardia, Incidence, Kidney Failure, Chronic, Length of Stay and Liver Function Tests.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Terlipressin in 41 patients.

The publication is from 2017 (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society), a journal based in United States.

More context: the Terlipressin compound page, all human trials.